EGFR and non-small cell lung carcinoma: Molecular tests, epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and programmed death-ligand 1 (PD-L1) expression have also been investigated in patients with early-stage NSCLC [8].